Synaptogenix Inc. has extended the employment of CEO Dr. Alan Tuchman until January 31, 2025, with a reduced salary of $12,500 per month, and has also entered into a consulting agreement with Dr. Daniel Alkon at a fee of $16,000 per month, effective January 1, 2025. Additionally, the company formed a special committee to explore strategic opportunities and terminated a clinical trial for Bryostatin-1 due to slow enrollment.